The Ensign Group Acquires 3 Skilled Nursing Facilities in Colorado

Acquisitions were effective April 1, 2021, and will be subject to a long-term, triple net lease.

April 6, 2021

The Ensign Group, Inc., the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational, and speech therapies, and other rehabilitative and healthcare services, announced today that it acquired the operations of the following skilled nursing facilities in Colorado:

These acquisitions were effective April 1, 2021, and will be subject to a long-term, triple net lease.

“We are pleased to be adding these operations to our Colorado portfolio and look forward to the contribution they will make to our same-store operations in the state,” said Barry Port, Ensign’s Chief Executive Officer.

Dave Jorgensen, President of Endura Healthcare, Inc., Ensign’s Colorado-based subsidiary, added, “Each of these operations is well situated to become the operation-of-choice in their markets. We are excited to work together with our healthcare partners as we strive to provide top-notch care for our patients and their families.”

This acquisition brings Ensign’s growing portfolio to 235 healthcare operations, 22 of which also include assisted living operations, across thirteen states. Ensign owns 94 real estate assets. Mr. Port reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, assisted living, and other healthcare-related businesses throughout the United States.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.